Detalhe da pesquisa
1.
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.
Cost Eff Resour Alloc
; 21(1): 6, 2023 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36647072
2.
Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
BMC Pulm Med
; 23(1): 69, 2023 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809990
3.
Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
BMC Cancer
; 22(1): 292, 2022 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303812
4.
Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
BMC Cancer
; 21(1): 689, 2021 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34112097
5.
Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
Cancer Med
; 13(3): e6827, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38213074
6.
Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP).
J Clin Pathol
; 76(5): 327-332, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903610
7.
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers.
JCO Precis Oncol
; 7: e2200546, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862967
8.
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
J Med Econ
; 26(1): 445-453, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883193
9.
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective.
Expert Rev Pharmacoecon Outcomes Res
; 22(6): 1033-1042, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35593180
10.
Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.
J Health Econ Outcomes Res
; 9(2): 134-146, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36475278
11.
Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
J Clin Pathol
; 75(3): 193-200, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722840
12.
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
Pharmaceuticals (Basel)
; 14(4)2021 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33918795
13.
Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD.
Int J Chron Obstruct Pulmon Dis
; 15: 1643-1654, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32764910
14.
Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.
Oncotarget
; 10(42): 4321-4332, 2019 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31303965
15.
Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
Farm Hosp
; 42(3): 95-102, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29730979
16.
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
Int J Chron Obstruct Pulmon Dis
; 11: 123-32, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26848262
17.
Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain / Impacto económico de olaparib en el tratamiento de mantenimiento de mujeres con cáncer de ovario epitelial seroso de alto grado en recaída, platino sensibles y con mutación BRCA en España
Farm. hosp
; 42(3): 95-102, mayo-jun. 2018. tab, graf
Artigo
em Inglês
| IBECS (Espanha) | ID: ibc-174823